Moderna (MODRNA) Q4 Loss Narrows to $117M

Net loss for the fourth quarter of 2025 narrows to $117 million, or $0.19 per share, versus a $169 million loss in the same period of 2024, according to the biotech firm's results released February 13, 2026. Revenue for the quarter rises to $287 million, up from $224 million in the prior-year period. The improvement follows continued delivery of its messenger RNA vaccines and a reduction in research and development expenses. The stock closed at $34.85 on February 13, 2026, down 1.2% on the day.